Important Notice: Normal Operations Despite Inclement Weather. Due to current weather conditions, we want to assure all patients that there are no delays in our services. We are continuing with normal operations and remain fully committed to providing the care you need. Please proceed with your scheduled appointments as planned. Stay safe! Exciting News! Our Gainesville Office has moved to Bristow – 9450 Innovation Drive, Manassas, VA 20110. Same great providers and care team, same exceptional care, new, larger space to better serve our patients.
A groundbreaking study published in June 2024 in The New England Journal of Medicine has introduced a promising new treatment for a specific type of advanced lung cancer. The research, co-authored by Alex Spira, MD, PhD, FACP, FACSO, Medical Oncologist and Co-Director of The Virginia Cancer Specialists Research Institute, highlights the combination of two drugs, amivantamab and lazertinib, in treating previously untreated non-small cell lung cancer (NSCLC) with certain genetic mutations.
Understanding the Study: The study focused on patients with EGFR mutations (specifically exon 19 deletion or L858R mutations) in advanced NSCLC. These mutations affect a protein called EGFR, which plays a crucial role in cancer growth. The trial compared the effectiveness of amivantamab plus lazertinib against the standard treatment, osimertinib, which is commonly used in such cases.
Key Findings: Researchers found that the combination therapy of amivantamab and lazertinib significantly extended the time patients lived without their cancer progressing compared to those treated with osimertinib alone. This means patients on the new combination had longer periods where their disease did not worsen.
“This groundbreaking study marks a significant advancement in the treatment landscape for advanced non-small cell lung cancer. The findings highlight the efficacy of combining amivantamab and lazertinib, offering substantial improvements in progression-free survival for patients with specific EGFR mutations. This represents a pivotal moment in personalized oncology, promising better outcomes and renewed hope for patients facing this challenging diagnosis.” Timothy McCarthy, MD, Virginia Cancer Specialists
Impact on Patients: Progression-Free Survival: Patients receiving amivantamab plus lazertinib had a median progression-free survival of 23.7 months, compared to 16.6 months with osimertinib alone. This is a substantial improvement, indicating better control over the disease. Overall Response: About 86% of patients on the combination therapy showed an objective response, meaning their tumors shrank or disappeared, comparable to 85% on osimertinib. Side Effects: The most common side effects included skin and nail problems, and some patients experienced infusion-related reactions. However, these were generally manageable with medical support.
What Does the Future Hold? While the study primarily focused on delaying cancer progression, longer-term follow-up is needed to confirm if this treatment combination also improves overall survival rates. Ongoing research will provide more insights into its lasting benefits and safety profile.
The combination of amivantamab and lazertinib represents a significant advancement in treating EGFR-mutated advanced NSCLC. This treatment not only improves outcomes compared to standard therapies but also offers hope for patients facing this challenging diagnosis. As always, consult with your healthcare provider to discuss whether this new option might be suitable for you based on your specific condition and medical history. This study marks a pivotal moment in personalized cancer care, paving the way for more effective treatments tailored to individual genetic profiles.
We here at Virginia Cancer Specialists are proud to be involved in this groundbreaking research, which continues to give our patients access to the most advanced and state-of-the-art treatments while remaining close to home. We are seeing real progress in the evolution of cancer care, and here at Virginia Cancer Specialists, we will continue to care for our patients with these exciting new treatments.
